HCPCS Code Q4132: Grafix Core and GrafixPL billing guide

Found our content helpful?

Key takeaways

HCPCS Code Q4132 covers Grafix Core and GrafixPL, chorion-derived placental membrane allografts billed per square centimeter.

Since January 1, 2026, Medicare pays Q4132 as an incident-to supply at a flat national rate of about $127.14 per square centimeter.

The CY2026 fee schedule and OPPS rules retired the high-cost and low-cost skin substitute payment groups along with the ASP add-on.

The 2026 skin substitute LCDs were withdrawn on December 24, 2025, so your MAC’s existing coverage policy still governs Q4132.

Every Q4132 claim needs a CPT application code from the 15271-15278 series and a supporting ICD-10 diagnosis code.

Practice management software like Pabau keeps wound measurements, product lot numbers and diagnosis codes on the same record, so the claim goes out complete.

HCPCS Code Q4132 is the Level II code for Grafix Core and GrafixPL, chorion-derived placental membrane allografts billed per square centimeter.

Since January 1, 2026, Medicare has paid it as an incident-to supply at a flat national rate of about $127.14 per square centimeter. Every claim also carries a CPT application code from the 15271-15278 series plus a supporting ICD-10 diagnosis code.

Denials on this code usually trace back to the chart rather than the code. A practice can identify Grafix Core correctly, calculate the square centimeters correctly, and still lose the claim. One missing wound measurement on the date of service is enough to sink it.

Skin substitute Q-codes carry some of the heaviest documentation scrutiny in outpatient billing, per CMS’s HCPCS program guidance.

This guide covers the official descriptor, the CY2026 payment rules, CPT pairing, ICD-10 codes, documentation requirements, and the denials that keep recurring.

HCPCS Code Q4132: Official descriptor and product details

HCPCS Code Q4132 is the Level II code assigned to Grafix Core and GrafixPL, billed per square centimeter.

Both products are chorion-derived placental membrane allografts originally developed by Osiris Therapeutics, which Smith+Nephew later acquired. Grafix Prime, the amnion-derived product in the same family, sits under a different code.

The code covers both product variants under a single descriptor because they share the same biological composition and clinical application profile.

Grafix Core is a viable cryopreserved placental membrane containing living cells, growth factors, and extracellular matrix components. GrafixPL is a processed form of the same tissue.

Both share the Q4132 code because CMS groups them by clinical equivalence, not by the presence or absence of viable cells. Billers should note that the correct code is Q4132 regardless of which specific variant is applied. Confusing the two with a different Q-code in the Grafix product family is one of the most common claim errors.

Q4132 fee schedule and Medicare reimbursement rates

Medicare pays Q4132 at a flat national rate of about $127.14 per square centimeter. That rate took effect on January 1, 2026 under the CY2026 Physician Fee Schedule final rule (CMS-1832-F).

CMS now treats skin substitutes that hold no Section 351 biologics license as supplies furnished incident to the application procedure. Grafix Core and GrafixPL are regulated as 361 HCT/Ps and hold no such license. Q4132 is therefore paid at the flat rate rather than at average sales price.

The quarterly ASP cycle no longer sets the payment amount for this code. CMS published the rate as $127.28 per square centimeter in the final rule, then corrected it to $127.14 on November 26, 2025.

The corrected figure matches the rate finalized in the CY2026 OPPS rule, so the office and hospital outpatient amounts agree.

Confirm the current amount in the CMS Physician Fee Schedule lookup tool before you bill. CMS has said it may update the rate annually using ASP data once that data reflects the new policy.

What replaced the high-cost and low-cost classification

Through CY2025, CMS sorted skin substitute products into high-cost and low-cost groups. That grouping decided whether the product was paid separately or packaged into the application procedure payment.

The CY2026 rules retired both groups. Payment now follows the product’s FDA regulatory pathway, and every pathway carries the same rate for 2026.

Under the CY2026 OPPS rule, CMS assigns skin substitutes to three payment groups by FDA pathway:

• APC 6000 for products approved through premarket approval (PMA)
• APC 6001 for products cleared through the 510(k) pathway
• APC 6002 for 361 HCT/Ps, which is where Grafix Core and GrafixPL sit

All three groups pay $127.14 per square centimeter for CY2026. CMS has signaled that it may set different rates by category in later years, so the category still matters.

The product is still paid separately from the application CPT code, but the amount no longer tracks what the practice paid for it. Budget for the product accordingly, and read your remittance advice to confirm how the supply line is paid in your jurisdiction.

Clinical indications: When to use Q4132

Q4132 applies when Grafix Core or GrafixPL is applied to a wound type covered by the Medicare policy in force for your jurisdiction. Coverage rules did not change on January 1, 2026, even though payment did.

Wound care teams that track wound measurements over time find it easier to demonstrate the treatment history Medicare requires. That history is what supports the move to an advanced skin substitute.

One caveat matters more than any other here. On December 24, 2025, CMS withdrew the skin substitute LCDs that were due to take effect on January 1, 2026. Those LCDs would have sorted products into covered and non-covered lists, and they never took effect. No such list governs Q4132 today.

Coverage still runs through the MAC policies that were already in place, and Novitas, First Coast and CGS each hold an active skin substitute policy.

Covered indications under the existing MAC policies typically include the following wound types:

• Diabetic foot ulcers (DFU) that have not healed with standard care over four or more weeks
• Venous leg ulcers (VLU) that have not responded to compression therapy over the standard trial period
• Pressure ulcers at stage 3 or stage 4 where conservative management has been exhausted
• Surgical wounds with complex closure needs meeting LCD criteria
• Partial-thickness burns in specific clinical scenarios covered by individual MAC LCDs

Contraindications include active wound infection, wounds with inadequate vascularity (untreated peripheral arterial disease), and patients with known hypersensitivity to placental tissue products.

The medical record must show that a qualified clinician evaluated the wound and that a standard-care trial was completed. It must also show that the patient meets each positive coverage criterion.

ICD-10 diagnosis codes that support Q4132 billing

Medicare requires at least one valid supporting ICD-10-CM diagnosis code on every Q4132 claim. Coding to the highest level of specificity is mandatory.

An unspecified ulcer code where a specific laterality or stage code exists will trigger an edit at the MAC level. The table below covers the most commonly used diagnosis codes for the primary Q4132 indications.

The diabetes codes carry no laterality of their own. E11.621 and E10.621 both read “with foot ulcer”. The side and the exact site come from a companion L97.4- or L97.5- code for the heel, midfoot or toes.

E11.622 is a different condition altogether: a type 2 diabetic skin ulcer away from the foot, which does not support a diabetic foot ulcer claim.

Cross-reference the diagnosis codes on every claim against the applicable MAC LCD. LCDs name the ICD-10-CM codes they cover in a structured list. A code that is absent from that list draws a denial even when the clinical picture clearly fits.

CPT application codes used with Q4132

HCPCS Code Q4132 covers the product. It does not cover the act of applying it. The application procedure must be billed separately using a CPT code from the 15271-15278 series, which are the skin substitute application codes.

Per the CMS CPT/HCPCS code list, these are the only application codes recognized alongside skin substitute Q-codes for Medicare billing purposes.

Code selection turns on two things: the anatomical site group and the total wound surface area. The sites split into two groups. One covers the trunk, arms and legs. The other covers the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet and digits.

Total wound surface area then picks the pair. Wounds under 100 sq cm in total take the 25 sq cm codes. Wounds of 100 sq cm or more take the 100 sq cm codes. Age changes nothing about which code applies.

It changes only the unit of measure: under 15273, 15274, 15277 and 15278, infants and children are measured as a percentage of body area.

The product applied never affects this choice, so Q4132 can pair with any code in the series. The CPT code covers the clinician’s work and Q4132 covers the product. Both must appear on the same claim for it to process. Submitting Q4132 without an application CPT code is one of the top reasons for denial.

Billing requirements and documentation checklist for Q4132

Thorough documentation is what separates a paid Q4132 claim from a denied one. Compliance requirements for skin substitute Q-codes are among the strictest in outpatient Medicare billing.

Practices that run those checks inside claims software for practices see fewer Q4132 rejections, because the missing elements surface before submission rather than after.

Required documentation elements for every Q4132 claim:

• Wound measurements on the date of service: length, width, and depth in centimeters. The square centimeter count billed must be mathematically supportable from these measurements.
• Standard-care trial documentation: evidence that the wound received appropriate standard care before the skin substitute was applied. That means moist wound dressings, compression for VLUs, or offloading for DFUs, for the required period.
• Product identification: the specific product applied (Grafix Core or GrafixPL), lot number, expiration date, and units used.
• Physician order: a signed order from the treating clinician authorizing the skin substitute application.
• Diagnosis code support: the chart must support the ICD-10-CM code reported on the claim. The record should document the wound type, chronicity, and any complicating conditions (e.g., peripheral neuropathy in a DFU patient).
• Covered diagnosis confirmation: the diagnosis code must appear on the applicable MAC LCD’s covered-diagnoses list.
• Bill type code: for hospital outpatient settings, use bill type 13X or 85X depending on facility type. Physician office claims bill under the professional claim.

Capture these elements at the point of care rather than reconstructing them at billing, which is where the most common audit findings start. Check before the application that the patient’s Medicare coverage is active. Check at the same time whether the MAC requires prior authorization for Q4132.

CY2026 CMS policy changes affecting skin substitute Q-codes

CMS rebuilt skin substitute payment policy for 2026, and the change is bigger than a rate adjustment. It affects every Q4132 claim submitted on or after January 1, 2026. A quarterly policy review is how a billing team catches a shift of this size before it shows up on a remittance advice.

What changed for Q4132 and related skin substitute Q-codes, and what did not:

• Skin substitutes became incident-to supplies: CMS-1832-F reclassified products that hold no Section 351 biologics license, including Q4132. Medicare pays them as supplies furnished with the application procedure.
• One flat rate replaced ASP pricing: the amount is about $127.14 per square centimeter, corrected from $127.28 on November 26, 2025. The same figure applies under OPPS.
• The high-cost and low-cost groups are gone: payment no longer turns on a cost group. OPPS now assigns products to APC 6000, 6001 or 6002 by FDA regulatory pathway.
• The 2026 skin substitute LCDs were withdrawn: CMS pulled them on December 24, 2025, before they took effect. There is no new covered or non-covered product list, and existing MAC policies still apply.
• Coverage rules did not change: frequency limits, standard-care trial requirements and covered diagnosis lists still come from your MAC’s current policy. Check them before billing a repeat application.

CMS publishes policy updates through MLN Matters articles and MAC-level coverage updates. Subscribe to your MAC’s listserv, and check for code-specific notes added during the annual HCPCS update cycle.

Common billing errors with Q4132 and how to avoid them

Q4132 generates a disproportionate share of claim denials relative to other outpatient HCPCS codes. Product-specific billing rules, diagnosis-code specificity and documentation volume all land on one claim line. Flag every Q4132 denial for root-cause analysis, because the same handful of errors recurs across claims.

The most frequent Q4132 denial reasons and how to address them:

A structured pre-submission review catches most of these errors before the claim leaves the practice. Retain the audit trail for every skin substitute claim, per the CMS record-keeping guidelines that apply to your setting.

To read the rejections these errors produce, start with the guide to denial codes, which explains the CARC codes attached to each denial type.

Related HCPCS codes: Q4132 vs Q4133 and other skin substitute Q-codes

Several HCPCS Q-codes cover amniotic and placental membrane products in the same clinical category as Q4132. Selecting the wrong code in this group is a common error, particularly for practices that stock more than one Grafix-family or competing placental product.

The AAPC HCPCS code database provides a searchable reference for the full Q-code skin substitute series.

Q4132 versus Q4133 is the most common code-selection error in this group, and Q4133 is broader than its Grafix name suggests. Its official descriptor covers four products: Grafix Prime, GrafixPL Prime, Stravix and StravixPL. Stravix and StravixPL are umbilical tissue grafts, so Q4133 is not a Grafix-only code.

Using Q4132 when Grafix Prime was applied is a coding error, and using Q4133 when Grafix Core was applied is the same error in reverse.

The product label and lot number in the chart are the definitive reference. Submitting a clean claim for Q4132 means the product in the chart and the code on the claim match exactly.

How Pabau keeps Q4132 documentation on the claim

In most wound care practices, a Q4132 claim is assembled from three places. The wound measurements sit in the clinical note. The product lot number sits on a sticker in a paper log. The diagnosis code gets picked later by whoever builds the claim. Those three only meet at submission, which is exactly where the mismatch surfaces.

Practice management software like Pabau keeps them together from the start. Wound length, width and depth are structured fields on the treatment note. The square centimeters billed then trace back to the record for that date of service. Product details and the standard-care trial history stay on the same patient timeline.

The diagnosis code attaches to the encounter rather than getting added afterwards, so the L97- site code and the E11- diabetes code travel together. Billing staff then work from a claim line that is already complete.

That turns the pre-submission review into a single check instead of a hunt through the chart. It also leaves the audit trail CMS expects if the claim is reviewed later.

Keep every Q4132 claim complete before it leaves

Pabau keeps wound measurements, product lot numbers and diagnosis codes on the same patient record, so the supply line and the chart agree. See how structured documentation cuts Q4132 denials.

Book a demo

Conclusion

Q4132 rewards practices that fix the chart rather than the claim. The code itself is straightforward. The work sits in the clinical workflow. That workflow has to capture wound measurements, standard-care trial history, product lot numbers and matched ICD-10 codes on the day of service.

Two 2026 changes work in your favor if you plan around them. Payment is now a predictable flat rate, so the product line no longer swings with quarterly ASP updates. Coverage still runs on your MAC’s existing policy, so the rules your team already knows still hold. Build the pre-submission check once and it carries the whole year.

Book a demo to see how Pabau keeps wound measurements, lot numbers and diagnosis codes on one complete Q4132 claim line.

Continue your research

Need to verify HCPCS codes in your billing workflow? Understanding medical billing fundamentals covers how HCPCS Level II codes integrate into the broader claim submission process.

Getting denials on your wound care claims? Denial management in healthcare walks through root-cause analysis and appeal strategies for common outpatient billing denials.

Want to reduce claim errors before submission? Submitting a clean claim outlines the pre-submission checks that prevent the most common HCPCS billing rejections.

Frequently asked questions